Regulators at the U.S. Food and Drug Administration declined to approve a needle-free nasal spray equivalent to an EpiPen, pending further study, according to the company developing it.
ARS Pharma developed the product, Neffy, which is inhaled and would have been available by prescription if approved.
Neffy would be a first-of-its-kind alternative to an EpiPen, which is commonly used to treat anaphylaxis, or severe allegoric reactions.
The FDA said they haven't yet seen enough evidence to support approval. The company will have an opportunity to run additional studies and apply for approval again.
'We are very surprised by this action and the late requirement at this time to change the repeat-dose study from a post-marketing requirement, which we had previously aligned on with FDA, to a pre-approval requirement, particularly given the positive Advisory Committee vote," Richard Lowenthal, CEO of ARS, said in a statement on Tuesday.
ARS shares fell sharply, dropping about 58% in pre-market trade on Wednesday morning.
This is a developing story. Please check back for updates.
2024-12-26 01:011633 view
2024-12-26 00:37374 view
2024-12-26 00:261399 view
2024-12-25 23:3183 view
2024-12-25 23:30174 view
2024-12-25 23:201749 view
DAMASCUS — Syrian rebel leader Ahmad al-Sharaa — better known as Abu Mohammed al-Golani — told Reute
The Alpha Artificial Intelligence AI4.0 investment system is an artificial intelligence trading syst
A suspect was taken into custody Saturday on murder charges in connection with the killing of a stud